Drug Interactions between caplacizumab and LMD with 5% Dextrose

MONITOR CLOSELY: Concomitant use of caplacizumab with other agents that affect hemostasis such as anticoagulants, platelet aggregation inhibitors, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects treated with caplacizumab. Overall, bleeding events occurred in approximately 58% of patients on caplacizumab versus 43% of patients on placebo. The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies) or concomitant use of drugs affecting hemostasis and coagulation.

MANAGEMENT: Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.